Loading the security page…
The series is stated in the current share scale after splits; dividends are not included in the price
Medtronic makes medical devices and nothing else, across a wider range than anyone: pacemakers, neuromodulation, surgery, diabetes.
The portfolio is the industry's broadest, which is both a strength and a weakness. The strength is resilience: weakness in one line is offset by others, and hospital relationships span many purchases at once. The weakness is pace: a large company grows more slowly than a specialist competitor in a single niche.
The lines investors watch most are pulsed-field treatment of cardiac rhythm disorders and continuous glucose monitoring with a pump. In both the company is catching up with competitors who arrived earlier, and the speed of that catch-up governs the market's view.
Revenue follows procedure volume and therefore hospital throughput. Regulatory requirements for devices are strict, and a batch recall is expensive and damaging — such cases exist in the company's history. Medtronic pays a dividend with a very long record of increases.
Based on the last 12 months of reports, through 31 July 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Medtronic plc. (MDT) is a company in the Health care sector; its shares trade on NYSE.
The price of Medtronic plc. (MDT) on November 2, 2026 is 99.00 $, +2.55 % on the day. Over 52 weeks the stock traded between 73.31 $ and 106.33 $; the price now sits 78 % of the way up that range. Over the past year the price changed by +0.12 %. The P/E ratio is 23.69, which is close to the sector median (24.61). Market capitalization is 123.91 billion $, rank 1 among 20 stocks of the same industry with a known capitalization.
Medtronic plc. trades on NYSE under the ticker MDT. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks MDT has traded between 73.31 $ and 106.33 $. As of 2 November 2026 the price stood 67.05 % of the way from the 52-week low to the high.
Over one year MDT shares rose 0.12 %; over six months they rose 11.44 %. Volatility over 90 days is 26.40 %. Dividends are not included: this is price change only, as of 2 November 2026.
MDT trades at a price-to-earnings ratio of 23.7, below the sector median of 24.6. Price to sales is 3.3, below the sector median of 3.6. Price to book is 2.5, above the sector median of 2.5. Calculated from reports for the period ending 31 July 2026.
Medtronic plc. reported revenue of 37.5B $ and net income of 5.2B $ over the last four quarters. Net margin is 13.93 %. Revenue changed by +9.77 % year over year. Earnings per share are 4.06 $. Market capitalisation is 123.9B $.
MDT has a return on equity of 10.41 %, above the sector median of −40.58 %. Return on assets is 5.61 %, above the sector median of −30.08 %. Operating margin is 18.08 %, above the sector median of −20.96 %.